Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MYOS RENS Technology earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.8066945350332 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

MYOS RENS Technology (NASDAQ:MYOS) traded up $0.11 during trading hours on Friday, hitting $1.61. 113,360 shares of the stock were exchanged, compared to its average volume of 152,643. The firm has a market capitalization of $10.86, a price-to-earnings ratio of -2.44 and a beta of 0.26. MYOS RENS Technology has a 1 year low of $1.12 and a 1 year high of $6.00.

MYOS RENS Technology (NASDAQ:MYOS) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $0.16 million during the quarter. MYOS RENS Technology had a negative return on equity of 71.14% and a negative net margin of 941.41%.

In other MYOS RENS Technology news, CEO Joseph Mannello acquired 38,119 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were purchased at an average price of $1.35 per share, for a total transaction of $51,460.65. Following the completion of the purchase, the chief executive officer now directly owns 233,629 shares of the company’s stock, valued at $315,399.15. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders bought 112,024 shares of company stock worth $151,529 in the last quarter. Company insiders own 45.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “MYOS RENS Technology (MYOS) Earns News Impact Score of 0.05” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/20/myos-rens-technology-myos-earns-news-impact-score-of-0-05.html.

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Insider Buying and Selling by Quarter for MYOS RENS Technology (NASDAQ:MYOS)

Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.